BR112014026040A2 - tablete de liberação sustentada que contém levodropropizina e método para preparar o mesmo - Google Patents

tablete de liberação sustentada que contém levodropropizina e método para preparar o mesmo

Info

Publication number
BR112014026040A2
BR112014026040A2 BR112014026040A BR112014026040A BR112014026040A2 BR 112014026040 A2 BR112014026040 A2 BR 112014026040A2 BR 112014026040 A BR112014026040 A BR 112014026040A BR 112014026040 A BR112014026040 A BR 112014026040A BR 112014026040 A2 BR112014026040 A2 BR 112014026040A2
Authority
BR
Brazil
Prior art keywords
preparing
levodropropizine
same
release tablet
sustained release
Prior art date
Application number
BR112014026040A
Other languages
English (en)
Other versions
BR112014026040B1 (pt
Inventor
Kyung Kim Bo
Gu Min Byung
Ju Kang Hyun
Sang Jang Jae
Min Cho Sang
Woong Choi Youn
Original Assignee
Korea United Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea United Pharm Inc filed Critical Korea United Pharm Inc
Publication of BR112014026040A2 publication Critical patent/BR112014026040A2/pt
Publication of BR112014026040B1 publication Critical patent/BR112014026040B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “tablete de liberação sustentada que contém levodropropizina e método para preparar o mesmo” trata-se de um tablete de liberação sustentada de levodropropizina que compreende: uma camada de liberação imediata que contém levodropropizina; e uma camada de liberação sustentada que contém levodropropizina e um polímero de controle de liberação.
BR112014026040-0A 2012-04-17 2013-04-17 Comprimido de liberação sustentada que contém levodropropizina BR112014026040B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0039907 2012-04-17
KR1020120039907A KR20130117128A (ko) 2012-04-17 2012-04-17 레보드로프로피진 함유 서방정 및 이의 제조방법
PCT/KR2013/003232 WO2013157841A1 (ko) 2012-04-17 2013-04-17 레보드로프로피진 함유 서방정 및 이의 제조방법

Publications (2)

Publication Number Publication Date
BR112014026040A2 true BR112014026040A2 (pt) 2017-06-27
BR112014026040B1 BR112014026040B1 (pt) 2022-02-22

Family

ID=49383726

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026040-0A BR112014026040B1 (pt) 2012-04-17 2013-04-17 Comprimido de liberação sustentada que contém levodropropizina

Country Status (8)

Country Link
EP (1) EP2839829B1 (pt)
KR (1) KR20130117128A (pt)
BR (1) BR112014026040B1 (pt)
ES (1) ES2693156T3 (pt)
PH (1) PH12014502325B1 (pt)
PL (1) PL2839829T3 (pt)
RU (1) RU2616263C2 (pt)
WO (1) WO2013157841A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102260235B1 (ko) * 2018-09-10 2021-06-03 콜마파마 주식회사 레보드로프로피진 방출제어형 이층정제 및 이의 제조방법
KR102246066B1 (ko) * 2019-02-12 2021-04-29 한국유나이티드제약 주식회사 레보드로프로피진 함유 서방정의 제조방법
CN110934872B (zh) * 2019-12-16 2023-01-10 太阳升(亳州)生物医药科技有限公司 左羟愈酚胶囊及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
KR101050076B1 (ko) * 2009-02-04 2011-07-19 한국유나이티드제약 주식회사 제어 방출성 아세클로페낙을 함유하는 경구 제제의 조성물 및 그의 제조방법
KR101246553B1 (ko) 2010-04-09 2013-03-26 현대약품 주식회사 서방성 약제학적 조성물 및 이의 제조방법
WO2011126327A2 (en) * 2010-04-09 2011-10-13 Hyundai Pharm Co., Ltd. Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
KR101272470B1 (ko) * 2010-09-30 2013-06-14 주식회사 바이오파마티스 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR101234254B1 (ko) * 2010-06-01 2013-02-18 한국유나이티드제약 주식회사 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제

Also Published As

Publication number Publication date
KR20130117128A (ko) 2013-10-25
EP2839829A4 (en) 2015-02-25
BR112014026040B1 (pt) 2022-02-22
EP2839829B1 (en) 2018-09-26
RU2616263C2 (ru) 2017-04-13
PL2839829T3 (pl) 2019-03-29
PH12014502325A1 (en) 2015-01-12
RU2014145845A (ru) 2016-06-10
ES2693156T3 (es) 2018-12-07
PH12014502325B1 (en) 2015-01-12
EP2839829A1 (en) 2015-02-25
WO2013157841A1 (ko) 2013-10-24

Similar Documents

Publication Publication Date Title
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2016002772A1 (es) Composiciones de insulina de rápida acción
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20150326A (es) Inhibidores de autotaxina
ECSP14013169A (es) Tableta a prueba de alteración que proporciona liberación inmediata del fármaco
ECSP13012519A (es) Compuestos sustituidos de benzamida
CR20140450A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
CR20140431A (es) Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
BR112016029465A2 (pt) chapa de aço elétrica
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
DOP2014000098A (es) 2-tiopirimidinonas
CO7200265A2 (es) Proceso para la preparación de 4-amino-5-flúor-3-halo-6-picolinatos(substituidos)
AU2014207408A8 (en) Pharmaceutical compositions comprising nitroxyl donors
EA201301061A1 (ru) Фармацевтическая композиция, содержащая инозит
BR112017008154A2 (pt) construção de gerenciamento de luz
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
BR112014032764A2 (pt) composição farmacêutica contendo fimasartana e hidroclorotiazida
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/04/2013, OBSERVADAS AS CONDICOES LEGAIS.